Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 288.00 | |
5 mg | In stock | $ 463.00 | |
10 mg | In stock | $ 678.00 | |
25 mg | In stock | $ 1,070.00 | |
50 mg | In stock | $ 1,430.00 | |
100 mg | In stock | $ 1,930.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 463.00 |
Description | JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy. |
Targets&IC50 | Rev1-Rev7:0.42 μM (Kd), Rev1-Rev7:0.78 μM (IC50) |
In vitro | JH-RE-06 unexpectedly causes dimerization of the REV1 CTD at its REV7-binding surface. It also blocks the REV1-REV7 interaction. |
In vivo | In mice, co-administration of JH-RE-06 with cisplatin inhibits the growth of xenograft human melanomas. JH-RE-06 suppresses mutagenic TLS and increases cisplatin-induced toxicity in cultured human and mouse cell lines [1]. |
Molecular Weight | 468.72 |
Formula | C20H16Cl3N3O4 |
CAS No. | 1361227-90-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5 mg/mL (10.67 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JH-RE-06 1361227-90-8 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis JH RE 06 inhibit Inhibitor JHRE06 inhibitor